Characterization of drug-specific T cells in lamotrigine hypersensitivity

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 6, 2003, Pages 1393-1403

  Naisbitt, Dean J ^a   Farrell, John ^a   Wong, Gavin ^a   Depta, Jan P H ^b   Dodd, Charlotte C ^a   Hopkins, Josephine E ^a   Gibney, Claire A ^a   Chadwick, David W ^a   Pichler, Werner J ^b   Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anticonvulsant hypersensitivity; Antigen processing; Chemokines; Cytokines; Lamotrigine; T cells; T cell receptors

Indexed keywords

2 METHYLLAMOTRIGINE; 3 METHYLLAMOTRIGINE; 4 METHYLLAMOTRIGINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA DQ ANTIGEN; HLA DR ANTIGEN; HOMING RECEPTOR; INTERLEUKIN 5; LAMOTRIGINE; LAMOTRIGINE N OXIDE; LYMPHOCYTE ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PERFORIN; PHENYTOIN; RANTES; T LYMPHOCYTE RECEPTOR; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CASE REPORT; CELL SPECIFICITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SPECIFICITY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE CLONE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION TEST; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY MECHANISM; SKIN; SYMPTOM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 0038797941     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1507     Document Type: Article

References (44)

1. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998;39:S8-16.
2. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.
3. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002;3:229-38.
4. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997;27:175-81.
5. Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanni MP, Schnyder B, et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001;31:1398-408.
6. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935;61:643-56.
7. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000;23:483-507.
8. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. Metabolic activation in drug allergies. Toxicology 2001;158:11-23.
9. + T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999;103:192-9.
10. Naisbitt DJ, Farrell J, Gordon SF, Maggs JL, Burkhart C, Pichler WJ, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol 2002;62:628-37.
11. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J Clin Invest 1997;100:136-41.
12. von Greyerz S, Zanni MP, Frutig K, Schnyder B, Burkhart C, Pichler WJ. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. J Immunol 1999;162:595-602.
13. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, Hari Y, et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J Clin Invest 1998;102:1591-8.
14. Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988;82:110-5.
15. Troger U, Brandt W, Rose W. Development of a pulmonary phenytoin-associated hypersensitivity reaction despite concomitant dexamethasone and prednisolone administration. Int J Clin Pharmacol Ther 2000;38:452-6.
16. Kahn HD, Faguet GB, Agee JF, Middleton HM, 3rd. Drug-induced liver injury. In vitro demonstration of hypersensitivity to both phenytoin and phenobarbital. Arch Intern Med 1984;144:1677-9.
17. + T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995;155:462-72.
18. Friedmann PS, Strickland I, Pirmohamed M, Park BK. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598-604.
19. Leyva L, Torres MJ, Posadas S, Blanca M, Besso G, O'Valle F, et al. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. J Allergy Clin Immunol 2000;105:157-65.
20. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JPH, Chadwick DW, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype and cytokine profile of drug-specific T-cell clones. Mol Pharmacol 2003;63:732-41.
21. Sachs B, Ronnau AC, von Schmiedeberg S, Ruzicka T, Gleichmann E. Schuppe HC. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology 1997;195:60-4.
22. Britschgi M, Steiner UC, Schmid S, Depta JP, Senti G, Bircher A, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001;107:1433-41.
23. 51Cr-labelled allogenic target cells in vitro: Inhibition by isoantibody and by drugs. Immunology 1968;14:181-6.
24. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, Pichler WJ. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction. Clin Exp Allergy 1998;28:1412-7.
25. + T cells from allergic individuals. J Immunol 2000;164:6647-54.
26. Maggs JL, Naisbitt DJ, Tettey JN, Pirmohamed M, Park BK. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000;13:1075-81.
27. Shimonkevitz R, Kappler J, Marrack P, Grey H. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med 1983;158:303-16.
28. Brown KL, Henderson DC, Nadel S, Tanveer A, Booy R. Carbamazepine hypersensitivity and the use of lymphocyte proliferation responses. Dev Med Child Neurol 1999;41:267-9.
29. Schaub N, Bircher AJ. Severe hypersensitivity syndrome to Lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000;55:191-3.
30. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, et al. MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A 2002;99:6181-6.
31. Van Snick J, Houssiau F, Proost P, Van Damme J, Renauld JC. I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis. J Immunol 1996;157:2570-6.
32. Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. Int Arch Allergy Immunol 1997;113:177-80.
33. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000;106:1171-6.
34. Hashizume H, Takigawa M, Tokura Y. Characterization of drug-specific T cells in phenobarbital-induced eruption. J Immunol 2002;168:5359-68.
35. Roujeau JC, Albengres E, Moritz S, Piacentino A, Cuny M, Revuz J, et al. Lymphocyte transformation test in drug-induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985;78:22-4.
36. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990;136:1053-68.
37. Gonzalez FJ, Carvajal MJ, Leiva L, Juarez C, Blanca M, Santamaria LF. Expression of the cutaneous lymphocyte associated antigen in circulating T cells in drug-allergic reactions. Int Arch Allergy Immunol 1997;113:345-7.
38. Gonzalez FJ, Leyva L, Posadas S, Luque I, Blanca M, Santamaria L, et al. Participation of T lymphocytes in cutaneous allergic reactions to drugs. Clin Exp Allergy 1998;28:3-6.
39. Blanca M, Posadas S, Torres MJ, Leyva L, Mayorga C, Gonzalez L, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy 2000;55:998-1004.
40. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001;56:890-6.
41. Wolkenstein P, Tan C, Lecoeur S, Wechsler J, Garcia-Martin N, Charue D, et al. Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem Biol Interact 1998;113:39-50.
42. von Greyerz S, Bultemann G, Schnyder K, Burkhart C, Lotti B, Hari Y, et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. Int Immunol 2001;13:877-85.
43. Zanni MP, von Greyerz S, Hari Y, Schnyder B, Pichler WJ. Recognition of local anesthetics by alphabeta+ T cells. J Invest Dermatol 1999;112:197-204.
44. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 2002;418:552-6.